{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:13:04Z","timestamp":1761174784943,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.cmi.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T23:56:07Z","timestamp":1550793367000},"page":"656-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["New potential biomarkers to assess efficacy of protection afforded by vaccine candidates against tuberculosis"],"prefix":"10.1016","volume":"25","author":[{"given":"M.A.","family":"Flores-Valdez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.02.010_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2019.02.010_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/resp.13272","article-title":"Update on tuberculosis biomarkers: from correlates of risk, to correlates of active disease and of cure from disease","volume":"23","author":"Goletti","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.cmi.2019.02.010_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijid.2016.10.018","article-title":"Novel approaches to tuberculosis vaccine development","volume":"56","author":"Kaufmann","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2019.02.010_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0015-2016","article-title":"Clinical testing of tuberculosis vaccine candidates","volume":"4","author":"Hatherill","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2019.02.010_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(18)30452-2","article-title":"Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study","author":"Harris","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.cmi.2019.02.010_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/14760584.2017.1341316","article-title":"Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers","volume":"16","author":"Kaufmann","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2019.02.010_bib7","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1183\/13993003.01012-2016","article-title":"Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis","volume":"48","author":"Petruccioli","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2019.02.010_bib8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4049\/jimmunol.1501996","article-title":"Bacillus Calmette\u2013Gu\u00e9rin (BCG) revaccination of adults with latent Mycobacterium tuberculosis infection induces long-lived BCG-reactive NK cell responses","volume":"197","author":"Suliman","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.cmi.2019.02.010_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41586-018-0439-x","article-title":"A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes","volume":"560","author":"Roy Chowdhury","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2019.02.010_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10773-5","article-title":"Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T cells differentiate latent from active tuberculosis","volume":"7","author":"Rakshit","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2019.02.010_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01394","article-title":"Latent Mycobacterium tuberculosis infection is associated with a higher frequency of mucosal-associated invariant T and invariant natural killer T cells","volume":"9","author":"Paquin-Proulx","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2019.02.010_bib12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/s41564-018-0231-6","article-title":"Host resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 expression","volume":"3","author":"Sallin","year":"2018","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cmi.2019.02.010_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006687","article-title":"Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease","volume":"13","author":"Scriba","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2019.02.010_bib14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.15252\/emmm.201606330","article-title":"Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis","volume":"8","author":"Zimmermann","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cmi.2019.02.010_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A functional role for antibodies in tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2019.02.010_bib16","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1073\/pnas.1611776114","article-title":"Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19300576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19300576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:21:37Z","timestamp":1761117697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19300576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1198743X19300576"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.02.010","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New potential biomarkers to assess efficacy of protection afforded by vaccine candidates against tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}